Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Cambridge Antibody Technology Stories

2013-07-02 08:26:38

MONROVIA, Calif., July 2, 2013 /PRNewswire/ -- Xencor, Inc. announced today that that it has entered into a technology license and option agreement to provide Merck, known as MSD outside the United States and Canada, access to one of Xencor's Fc engineering patents for a therapeutic monoclonal antibody. Under the agreement, Merck will be granted a non-exclusive license to a Xencor patent for use in an undisclosed product, as well as an option to license the same intellectual property...

2013-06-28 20:22:37

TSX: AMF TORONTO, June 28, 2013 /CNW/ - Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for year ended March 31, 2013. "We continue to advance our diagnostic and therapeutic antibody programs and have recently reached a number of critical milestones", said Dr. Robert Gundel, Amorfix President and Chief Executive Officer.  "On the cancer front,...

2013-05-31 12:23:09

Treatment for Autoimmune and Other Diseases AUSTIN, Texas, May 31, 2013 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced today its development of a novel True Human(TM) therapeutic antibody. The Company reports that the antibody neutralizes a pro-inflammatory molecule known as interleukin-6 (IL-6). Agents targeting IL-6 have been effective therapy for a number of autoimmune or oncology-related diseases. Other therapeutic antibody products targeting IL-6...

2013-04-23 08:32:32

HERZLIYA-PITUACH, Israel, April 23, 2013 /PRNewswire/ -- Immune Pharmaceuticals Ltd. ("Immune"), a privately held Israeli company, announced today that the company's CEO Daniel Teper is the moderator of this morning's BIO International Convention breakout session "Can Israel Become the Next BioTech Startup Nation?" The panel, which will take place from 9:00 am - 9:45 am CT today at the conference in Chicago, IL, USA, will bring together life science thought leaders to discuss high-tech...

2013-04-09 12:29:00

BURLINGAME, Calif., April 9, 2013 /PRNewswire/ -- Igenica, Inc., an innovative biopharmaceutical company focused on the discovery and development of first-in-class antibody-based therapeutics for the treatment of cancer, today announced the appointment of Thi-Sau Migone, Ph.D., to the role of Chief Scientific Officer. Dr. Migone brings wide-ranging experience in the discovery and development of novel therapeutic antibodies. Dr. Migone joins Igenica from Human Genome Sciences,...

2013-04-01 08:23:18

LOS ANGELES, April 1, 2013 /PRNewswire/ -- ImaginAb, Inc., a clinical-stage company developing in vivo molecular imaging agents based on antibody technology, today announced that it has changed its name to AmaginAb. During a 'strategy meeting' at a recent employee team-building event, the Company's management belatedly realized that most of the important companies in the biotechnology space begin with the letter 'A'. "It became clear by the third hot chocolate one evening during our annual...

2013-01-22 08:31:36

PISCATAWAY, N.J., Jan. 22, 2013 /PRNewswire/ -- GenScript and Open Monoclonal Technology, Inc. (OMT) today announced a joint road show with potential clients across the US, China, Japan and South Korea in late January and early February. The road show will offer prospective clients introductions to GenScript and OMT's human antibody discovery technologies and explore new ways of accelerated and improved development of this important class of human therapeutics. GenScript...

2012-11-11 16:20:29

BURLINGAME, Calif., Nov. 11, 2012 /PRNewswire/ -- Apexigen, an emerging biopharmaceutical company dedicated to the discovery and development of best-in-class therapeutic monoclonal antibodies, announced today that its partner, Simcere Pharmaceutical Group (NYSE:SCR) of Nanjing, received approval from the State Food and Drug Administration of China to begin first-in-man trials with APX003, which is also known as BD0801, for the treatment of cancer. With this approval, APX003/BD0801 becomes the...

2012-11-05 12:26:12

MARTINSRIED, Germany and MUNICH and MONROVIA, Calif., Nov. 5, 2012 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and US-based Xencor, Inc. today announced the online publication of first clinical data on the anti-CD19 antibody MOR208 (MOR00208/XmAb5574) in the American Society of Hematology Annual Meeting Abstracts issue of the peer-reviewed medical journal Blood. MOR208 showed encouraging signs of preliminary anti-tumor activity and an acceptable...

2012-09-17 22:21:14

CAMBRIDGE, England, September 18, 2012 /PRNewswire/ -- First human antibody strain from its advanced discovery platform Kymab, a monoclonal antibody biopharmaceutical company, announced today the launch of Kymouse HK, the first strain from the innovative Kymouse(TM) antibody discovery platform, which enables rapid discovery of high affinity antibody drug candidates. Kymouse HK is a transgenic mouse that has been designed to produce a diverse repertoire...